ClinicalTrials.gg
Active, not recruitingNCT05769153NOVA-1Updated Aug 27, 2026

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 1/2 interventional study of AR-14034 SR implant lower dose and AR-14034 SR implant higher dose in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Alcon Research. Active, not recruiting at 42 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Alcon Research (part of Alcon) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Macular Degeneration by Alcon — none open to participants now, 1 under way, none of them phase 3. Macular Degeneration · Alcon.

Enrollment
7th of 16
139 · median 113
Started
2023
the only one that year
Phase 1/2
3 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies in Macular Degeneration by Alcon, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 1/2, and was the 18th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 18 studies in Macular Degeneration by Alcon is open now. The open studies under Macular Degeneration, anywhere →

Where they have run

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Macular Degeneration by Alcon as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

Read the detailed description

This study will be conducted in two stages. Stage 1 is a 48-week, dose-escalation, open-label evaluation of AR-14034 SR. Two cohorts will be enrolled, for an approximate total of 10 subjects. Subjects will receive AR-14034 SR in one of two dose levels and attend visits through Week 48 for assessment of safety and preliminary treatment effects.

Stage 2 is a 56-week (plus extension) double-masked, active comparator, randomized, parallel group evaluation of AR-14034 SR compared with aflibercept. Approximately 130 subjects will be enrolled and randomized 2:2:1 to AR-14034 SR one injection, AR-14034 SR two injections, or aflibercept dosed as labelled. Subjects will attend visits through Week 56 for assessment of safety and treatment effects. A 16-week open label extension phase will be conducted thereafter.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (nAMD)

Keywords

  • nAMD
  • retina
  • eyes
  • ophthalmology
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria [Stage 1 and Stage 2]:

  • Presence of an active choroidal neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD);
  • Best corrected visual acuity (BCVA) between 80 and 35 letters (20/25 to 20/200 Snellen equivalent) in the study eye;
  • BCVA greater than 20 letters (approximately 20/400 Snellen equivalent) in the non-study eye;
  • Media clarity and pupillary dilation in the study eye sufficient for all planned study procedures;
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol;
  • Other protocol-specified inclusion criteria may apply.

[Stage 1]:

  • Greater than or equal to 3 and less than or equal to 6 prior treatments of an ocular anti-VEGF medication within the 8 months prior to Screening in the study eye, with demonstrated anatomic response, as assessed by the Investigator.

[Stage 2]:

  • Treatment-naïve, or diagnosis of exudative neovascular age-related macular degeneration (nAMD) in the study eye.

Key Exclusion Criteria [Stage 1 and Stage 2]:

  • History or current ocular disease in the study eye other than nAMD, that, might require medical or surgical intervention during the study;
  • Structural damage to the macula that is likely to preclude improvement in visual acuity in the study eye after resolution of the nAMD;
  • Any active intraocular or periocular infection or active intraocular inflammation;
  • Treatment with ocular anti-VEGF product in the study eye within 28 days before Week 1 [Stage 1] or within 56 days before Screening [Stage 2].
  • Uncontrolled glaucoma in the study eye;
  • Uncontrolled blood pressure;
  • Females of who are pregnant, intending to become pregnant, nursing, or who are not willing to use an acceptable form of for the duration of the study;
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Stage 1)

    One intravitreal (IVT) injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR lower dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.

    Drug: AR-14034 SR implant lower dose · Drug: Aflibercept Injection

  • Experimental
    Cohort 2 (Stage 1)

    One IVT injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR higher dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.

    Drug: AR-14034 SR implant higher dose · Drug: Aflibercept Injection

  • Experimental
    AR-14034 SR one injection (Stage 2)

    One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR at Week 2. Sham procedures will be performed between Baseline and Week 52 when other arms are receiving scheduled treatment injections.

    Drug: AR-14034 SR implant · Drug: Aflibercept Injection · Drug: Sham procedure

  • Experimental
    AR-14034 SR two injections (Stage 2)

    One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with IVT insertions of AR-14034 SR at Week 2 and Week 6. Sham procedures will be performed between Baseline and Week 52 when other arms are receiving scheduled treatment injections.

    Drug: AR-14034 SR implant · Drug: Aflibercept Injection · Drug: Sham procedure

  • Active comparator
    Aflibercept (Stage 2)

    One IVT injection of aflibercept 2 mg at Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48. Sham procedures will be performed between Baseline and Week 52 when other arms are receiving scheduled treatment injections.

    Drug: Aflibercept Injection · Drug: Sham procedure

Interventions

  • DrugAR-14034 SR implant lower dose

    AR-14034 SR administered as an intravitreal implant

  • DrugAR-14034 SR implant higher dose

    AR-14034 SR administered as an intravitreal implant

  • DrugAR-14034 SR implant

    AR-14034 SR administered as an intravitreal implant

  • Aflibercept administered as a 2 milligram (mg) intravitreal injection

  • DrugSham procedure

    Needleless syringe used to simulate an intravitreal injection

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in ETDRS BCVA at the average across two visits, Weeks 44 and 48 (Stage 2)

    Visual acuity will be measured after manifest refraction using Early Treatment of Diabetic Retinopathy Study (ETDRS) letter charts in a 4-meter lane under standard illumination. Best corrected visual acuity (BCVA) will be recorded as the number of letters read correctly. The difference between the average across Weeks 44 and 48, and the baseline visit will be reported. One eye (study eye) will contribute to the analysis.

    Time frame: Baseline, Week 44, Week 48

Secondary outcomes

  1. Mean change from baseline in ETDRS BCVA by visit (Stage 2)

    Visual acuity will be measured after manifest refraction using ETDRS letter charts in a 4-meter lane under standard illumination. BCVA will be recorded as the number of letters read correctly. The difference between a given post-baseline visit and the baseline visit will be reported. One eye (study eye) will contribute to the analysis.

    Time frame: Baseline to Week 56

  2. Mean change from baseline in Central Subfield Thickness (CST) by visit (Stage 2)

    Central subfield thickness (CST) will be assessed using spectral domain optical coherence tomography (SD-OCT) imaging and measured in micrometers. The difference between a given post-baseline visit and the baseline visit will be reported. One eye (study eye) will contribute to the analysis.

    Time frame: Baseline to Week 56

07

Study locations

42 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 15, 2023
StartActual
Dec 6, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05769153
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Dec 6, 2023
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Director of Clinical Development, Alcon
study director · Alcon Research, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion